Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Apr 30;22:436–445.

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Molecular Vision.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited, used for non-commercial purposes, and is not altered or transformed.

PMC Copyright notice

Concentrations of tenascin-C in the vitreous collected from eyes with a macular hole (MH) or eyes with proliferative diabetic retinopathy (PDR). A: Tenascin-C concentrations in vitreous samples collected from eyes with a macular hole (MH; n=41) and eyes with proliferative diabetic retinopathy (PDR; n = 133). B and C: Correlations between vitreous concentrations of tenascin-C and periostin (B), or tenascin-C and VEGF (C) in eyes with PDR (n = 133). B: There is a significant correlation between the vitreous concentration of tenascin-C and periostin (r = 0.470, P <0.001; Spearman correlation coefficient). C: There is a weak correlation between tenascin-C and VEGF in the same patients with PDR (r = 0.198, P = 0.040; Spearman correlation coefficient). D: Vitreous concentrations of tenascin-C in eyes with fibrovascular membranes (FVMs; n=90) compared to those eyes without (n=43). *p <0.05, **p <0.001. Bars are mean ± standard error of the mean (SEM). N is number of patients.